Congress moves to block consumer ads for newly approved drugs for 3 years, with limited waiver option
This bill is currently sitting in the House Committee on Energy and Commerce. It has not seen any action since February 2025, which means it has been stalled for about 16 months. The committee must review the bill before it can move forward, but most bills like this never receive a vote.
No action since February 2025
This bill’s path across every version that has carried it.
Reintroduced
Reintroduced from H.R. 9142 (118th), which died when its Congress ended.
H.R. 9142 (118th) →How this policy affects specific groups of people
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
White House memo directs tougher enforcement of existing direct-to-consumer drug ad rules, including on social media; related policy area but not this specific 3-year post-approval ban bill.
Reports on senators proposing a broad ban on direct-to-consumer drug ads and references earlier legislation to restrict ads in the first three years after FDA approval (the same concept as this bill).
No votes or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Responsibility in Drug Advertising Act of 2025
Analysis generated by AI. Always verify with official sources.